Podcasts about genetech

Is there a cure for food allergies? Unfortunately, not yet. However, exciting new treatments are emerging that offer hope and improved quality of life for those managing food allergies. Dr. Maya N. Gharfeh joins us to explore innovative options for treating food allergies. In this episode, we cover comprehensive strategies ranging from traditional avoidance techniques to cutting-edge treatments like omalizumab (Xolair) and Oral Immunotherapy (OIT). While these treatments are promising, they are not cures. Dr. Gharfeh shares valuable insights on integrating these options into your allergy management plan. She also discusses how to determine whether Xolair or OIT might be the right choice for you or your child. Despite advancements, avoidance remains the cornerstone of food allergy management and must still be practiced even while undergoing treatment. What We Cover in the Episode about Food Allergy Treatment Options Effective methods for food allergy avoidance Deciphering packaged food labels and "may contain" statements Understanding cross-contamination and cross-contact Insights into Xolair and its role in food allergy treatment An overview of Oral Immunotherapy (OIT) Guidance on choosing between Xolair and OIT GUIDE: Food Allergen Alternative Names on Labels Produced in partnership with The Allergy & Asthma Network. Thanks to Genetech for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Have you ever wondered what happens inside your body during an allergic reaction? From itchy eyes to anaphylaxis, the science behind allergies explains why some reactions are mild while others can be life-threatening. In this episode, we break it all down. Dr. Payel Gupta and Kortney unpack the basics of food allergies, starting with what IgE antibodies are and how they play a role in allergic reactions. They explain what happens when your immune system encounters an allergen, breaking it down with our favorite pinata analogy. This deep dive into the immune system reveals why reactions can range from mild to life-threatening and explores the differences between food allergies, intolerances, and oral allergy syndrome. If you're newly diagnosed or curious about the science behind allergies, this episode offers valuable insights to help you understand your body and stay safe. What we cover in our episode about what happens in an allergic reaction What is an allergic reaction? Discover how your immune system identifies allergens and triggers a response involving IgE antibodies, mast cells, and histamine. Confused? We use our pinata analogy to simplify it. The role of histamine and inflammation. Learn how histamine is released during an allergic reaction, leading to inflammation and common symptoms. Understanding food allergies vs. food intolerances. Explore the key differences, including symptoms, risks, and why terminology matters. Oral allergy syndrome and environmental allergies. Understand why some allergies don't lead to anaphylaxis and how cross-reactivity can cause symptoms. Anaphylaxis and severe reactions. Explore why some reactions are life-threatening and how factors like exposure levels and health conditions can influence severity. More resources about allergies:  A Complete Guide to Allergies More About Food Allergies More About Anaphylaxis Food Allergy Treatment & Management Living with food allergies guide What Can You Do If You Can't Afford Allergen-Free Foods? What if I Can't Afford My Allergy Medications? This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Genetech for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement.

“As a society, we can no longer afford the human and economic cost of not putting more emphasis on the health of women.” -- Stephanie Sassman “Bikini medicine,” the assumption that a woman's health and wellbeing is the same as a man's except for the parts that are covered by a bikini, is woefully misguided. On this episode of The Medical Alley Podcast, Melinda Morimoto (Sr. Benefits Director) and Stephanie Sassman (Portfolio Leader, Women's Health) of Genentech explain why that mentality impacts the personal and professional wellbeing of women and how companies like Genetech are combating it with an array of workplace benefits both large and small. Learn more about Roche's XProject. Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

In episode 81 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Betsy Beggs of Goldman Sachs. At 23 years old, Betsy was a young professional finding her footing in New York City when she was blindsided by a stage 4 ALK+ lung cancer diagnosis. Tune in as she bravely shares her cancer story. For more, listen to Sarah Beggs, Betsy's mother, share her story from a parent perspective: youtu.be/05CrU4ltf80

En este capítulo hablamos de la historia de Novo Nordisk, la empresa farmacéutica danesa que ha revolucionado el tratamiento de la diabetes a nivel mundial. Desde sus antecedentes con August y Marie Krogh, el descubrimiento de la insulina, cómo empezó siendo una pequeña empresa dedicada a producirla y hasta convertirse en un líder global en biotecnología, exploramos cómo Novo y Nordisk llegan a unir fuerzas, y como ha impulsado avances médicos que han mejorado la vida de millones de personas. Hablamos sobre sus innovaciones en tratamientos para la pérdida de peso, su impacto en la salud pública y las estrategias que está implementando para mantenerse en el mercado.Capítulos00:00 Inicio00:49 Introducción05:20 Inicios August Krogh15:43 Alianza con Leo y creación de Nordisk21:40 Novo29:00 Era Hagerdon31:32 Guerra y Post guerra35:40 Los 70s el cambio ganador, ¡EUA!39:55 Los 80s Genetech, obesidad y fusión55:15 GLP 1 - El descubrimiento1:01:15 El Veneno1:04:15 GLP-1 en Novonordisk1:11:50 Johann Hari1:20:05 El crecimiento de NovoNordisk post GLP-11:24:10 Lecciones1:27:35 CierreLas opiniones expresadas en este podcast son eso, opiniones, no somos expertas en investigación ni periodistas. Probablemente habrá algunas inconsistencias y datos omitidos. No es nuestra investigación, es una compilación de información pública, referencias:https://www.youtube.com/watch?v=laPaezEsteIhttps://www.youtube.com/watch?v=0YMnHNIuK3Mhttps://novonordiskfonden.dk/en/who-we-are/our-history/https://www.rciscience.ca/100-lives/august-and-marie-kroghhttps://definingmomentscanada.ca/insulin100/history/novo-nordisk/ Hosted on Acast. See acast.com/privacy for more information.

As the Biologist, Researcher and two-time Pulitzer Prize winner, Edward Osborne Wilson stated, “In our attempt to make scientific discoveries every problem is an opportunity and the more difficult the problem the greater will be the importance of its solution”. With that in mind welcome to this latest episode in the Investing Matters podcast series with the hugely talented and globally respected, Dr. Jeremy Skillington, the Scientist, Biotechnologist, Entrepreneur and CEO of London AIM listed, £50 million market cap Poolbeg Pharma. Poolbeg Pharma plc is a biopharmaceutical company that is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases. Jeremy whose father worked at a Pfizer manufacturing plant in Cork, Ireland, “Always had an interest in the sciences”. Which would first take him to Munster Technical University where he attained his Diploma in Food Science and Technology, followed by his Biochemistry, Bachelor of Science Degree with Honours from the University of Galway (UoG). He also later attained his Biochemistry PhD from UoG. After completing his PhD Jeremy did Postdoctoral research at the University of California, San Francisco for three years before entering the Biotech industry in the Business Development group at Genentech in California in 2002. Throughout his time at Genetech up to 2009 Jeremy played a significant role in executing over forty licensing, investment and collaborations with biotech companies globally. Jeremy recalls, “how he learned so much from this hard-working, driven, smart but friendly and supportive Genetech Business Development team. With two stand out people in those early days, being his hiring manager, Dr Jonathan Lewis, an Oxford educated Immunologist and investment banker, and an industry veteran, Dr Jack Obijeski. Who both took him under their wings and showed him the biotech ropes. Since returning to Ireland in 2009, Dr Jeremy Skillington has crammed in an awful lot globally, including investing in the Medtech space, being the third employee of the very significant Irish biotech firm Inflazome, which after a mere four years achieved a landmark exit in September 2020 when it was purchased by Swiss drug giant Roche, This after Inflazome's leadership team with Jeremy heading up its business development had driven its phenomenal success. Then in 2021 he took “the call“ from seasoned serial entrepreneur Cathal Friel to become the CEO of Poolbeg Pharma. Jeremy has held that role since mid-2021 prior to Poolbeg Pharma's AIM listing in July 2021. Dr Jeremy Skillington, CEO of Poolbeg Pharma now has over twenty-one years' experience in the biotech industry, please listen to his fascinatingly insightful Investing Matters interview. As he shares insights on the global and Irish MedTech, Pharma, Biotech industry, angel investing via the Medtech Syndicate, the importance having “skin in the game”, leading and investing his money into Poolbeg Pharma's long-term potential, due to its world class leadership team and robust pipeline of innovative products and much more.

Siddhartha Sharan is a Senior Data and Applied Scientist at Microsoft, helping product teams make data-driven decisions. Currently he is working on an AI product built with OpenAI APIs for sentiment analysis. We talked about how he evaluates AI products built with large language models at Microsoft, product data science, and how he went from a business background to data science. Subscribe to Daliana's newsletter on www.dalianaliu.com for more on data science and career. Sid's LinkedIn: https://www.linkedin.com/in/siddharthasharan/ Daliana's Twitter: https://twitter.com/DalianaLiu Daliana's LinkedIn: https://www.linkedin.com/in/dalianaliu/ (00:00:00) Introduction(00:05:20) How does Microsoft evaluate AI product(00:16:17) Using OpenAI API for sentiment analysis(00:25:29) Microsoft data science team culture(00:26:52) DS, PM collaboration(00:28:29) Three steps to build trust in data science(00:30:13) How did he got into Microsoft(00:34:09) Level up in Genetech(00:36:09) ML engineer vs Product DS(00:37:43) Core skills in product DS(00:40:20) Hiring(00:42:47) How to deal with burnout(00:45:03) Should you over work to earn trust?(00:45:44) Daliana's story about first day at Amazon(00:49:54) Will AI replace data scientists?(00:51:32) Data scientist's role of GenAI(00:54:32) How to keep up with GenAI

Rodger's Secret Stash of Theories. Still battered and bruised after the fierce encounter at Precinct 4, and in no condition to confront Genetech goons, the crew sought refuge deeper in the Mushroom Forest. As they huddled among the towering mycelial giants, the atmosphere grew tense. Rodger seized the opportunity to delve into CeCe's enigmatic past. Stories of shadowy affiliations filled the air, casting an eerie vibe over their temporary sanctuary.Support the show

This week, as we approach the end of Pride Month, the GOLD team looks into how the industry can proactively support patients and staff who are part of the LGBTQ+ community.   Join Isabel and Jade as they look at how the industry can avoid 'rainbow washing' and tokenism to drive a positive change both inside and outside their organisations. This will include highlighting effective initiatives from BMS, GSK, Genetech and Pfizer, who like many others, are committed to supporting the community during Pride Month and beyond.   If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Confronting health inequities for transgender patients Reverse mentoring: a how-to guide 4 top tips to create the perfect ERG Last week's episode: What will it take to transform cancer care?

If you were to ask a random group of leaders if they'd heard of executive presence, almost all of them would answer yes. But if you asked that same group of leaders how many could clearly describe what executive presence is, few if any would answer this question in the affirmative. But if executive presence is key to leadership development and success, why are so few of us capable of explaining it? And if we can't explain it, how can we develop it? Those are questions I explore with my guest, Joel Garfinkle, in this episode of my “Leadership Biz Cafe” podcast. Joel is the author of 11 books and over 300 articles on leadership. He's been recognized by Global Gurus as one of the Top 30 global coaching experts, and his executive coaching clients include Google, Amazon, Microsoft, Oracle, Deloitte, Ritz-Carlton, Genetech, NBC, and the NBA. Joel was one of the first guests I spoke to when I started my podcast over a decade ago, which is why I'm delighted to speak with him again, this time about his latest book, “Executive Presence: Step Into Your Power, Convey Confidence, & Lead With Conviction”. It's a revealing conversation with some practical insights on how every leader – regardless of their gender or race – can develop and strengthen their executive presence and with it, become a better leader in their organization. https://open.spotify.com/episode/35QXOSIRIqwxM3nMZm4CqC?si=ca70672414924e00 Noteworthy links: Buy Joel's book “Executive Presence” on Amazon*. Learn more about Joel's work on his website. Listen to Joel's previous appearance on Leadership Biz Cafe. *sponsored link that helps to support this podcast. As an Amazon Associate I earn from qualifying purchases.

Sofia is a Lab Services and Media Prep Technician at Genetech. Hear how Sophia went from a degree in world languages to a community college biotech program. Sophia shares her story and journey in this episode and has advice for folks who want to transition careers and start work as a technician. The Talking Technicians podcast is produced by MNT-EC, the Micro Nano Technology Education Center, through financial support from the National Science Foundation's Advanced Technological Education grant program.Opinions expressed on this podcast do not necessarily represent those of the National Science Foundation.Join the conversation. If you are a working technician or know someone who is, reach out to us at info@talkingtechnicians.org.Links from the show:The Micro Nano Technology Education Center (MNT-EC): https://micronanoeducation.org/City College of San Francisco Biotechnology Program: https://www.ccsf.edu/degrees-certificates/biotechnologyGenetech: https://careers.gene.com/us/enEpisode Web Page: https://micronanoeducation.org/students-parents/talking-technicians-podcast/

Throw back to Mariah Matthews, who at the time was a project manager for Genetech.Please enjoy this audio from a previous television show.Support the show

There's rarely an expected path in science. This week's episode, produced in partnership with The Carl R. Woese Institute for Genomic Biology, features two stories from scientists of their cutting-edge research institute at the University of Illinois Urbana-Champaign who took unexpected journeys to get where they are today. Part 1: After a troubling personal experience with the health care system, Heng Ji decides to try to fix it. Part 2: When Brendan Harley is diagnosed with leukaemia in high school, it changes everything. Heng Ji is a professor at Computer Science Department, and an affiliated faculty member at Electrical and Computer Engineering Department of University of Illinois at Urbana-Champaign. She is also an Amazon Scholar. She received her B.A. and M. A. in Computational Linguistics from Tsinghua University, and her M.S. and Ph.D. in Computer Science from New York University. Her research interests focus on Natural Language Processing, especially on Multimedia Multilingual Information Extraction, Knowledge Base Population and Knowledge-driven Generation. She was selected as "Young Scientist" and a member of the Global Future Council on the Future of Computing by the World Economic Forum in 2016 and 2017. She was named as part of Women Leaders of Conversational AI (Class of 2023) by Project Voice. The awards she received include "AI's 10 to Watch" Award by IEEE Intelligent Systems in 2013, NSF CAREER award in 2009, PACLIC2012 Best paper runner-up, "Best of ICDM2013" paper award, "Best of SDM2013" paper award, ACL2018 Best Demo paper nomination, ACL2020 Best Demo Paper Award, NAACL2021 Best Demo Paper Award, Google Research Award in 2009 and 2014, IBM Watson Faculty Award in 2012 and 2014 and Bosch Research Award in 2014-2018. She was invited by the Secretary of the U.S. Air Force and AFRL to join Air Force Data Analytics Expert Panel to inform the Air Force Strategy 2030. She is the lead of many multi-institution projects and tasks, including the U.S. ARL projects on information fusion and knowledge networks construction, DARPA DEFT Tinker Bell team and DARPA KAIROS RESIN team. She has coordinated the NIST TAC Knowledge Base Population task since 2010. She was the associate editor for IEEE/ACM Transaction on Audio, Speech, and Language Processing, and served as the Program Committee Co-Chair of many conferences including NAACL-HLT2018 and AACL-IJCNLP2022. She is elected as the North American Chapter of the Association for Computational Linguistics (NAACL) secretary 2020-2023. Her research has been widely supported by the U.S. government agencies (DARPA, ARL, IARPA, NSF, AFRL, DHS) and industry (Amazon, Google, Facebook, Bosch, IBM, Disney). Heng Ji is supported by NSF AI Institute on Molecule Synthesis, and collaborating with Prof. Marty Burke at Chemistry Department at UIUC and Prof. Kyunghyun Cho at New York University and Genetech on using AI for drug discovery. Dr. Brendan Harley is a Professor of Chemical and Biomolecular Engineering at the University of Illinois at Urbana-Champaign. His research group develops biomaterial that can be implanted in the body to regenerate musculoskeletal tissues or that can be used outside the body as tissue models to study biological events linked to endometrium, brain cancer, and stem cell behavior. He's a distance runner who dreams of (eventually) running ultramarathons. Follow him @Prof_Harley and www.harleylab.org. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to the Juras-Sick Park-Cast podcast, the Jurassic Park podcast about Michael Crichton's 1990 novel Jurassic Park, and also not about that, too.  Find the episode webpage at: Episode 34 - The Main Road. In this episode, my terrific guest ReBecca Hunt-Foster joins the show to chat with me about:   State nomenclature, grade school dinosaur units, paleontologist origins stories, Arkansaurus fridayi, ornithomimids, Dr. James H. Quinn, Dinosaur National Monument and its history, deinocheirus, Kimmeridgian Morrison Formation, Moab and Nedcolbertia, all the famous dinosaurs: stegosaurus, apatosaurus, allosaurs, and more!, reading Jurassic Park, Colorado State Fossil Stegosaurus, a baby stegosaurus!, running stegosaurs, the thagomizer, camptosaurus, dryosaurus, sauropods, and more on stegosaurs, their thagomizers, their necks, their tales, injuring allosaurs, describing the Late Jurassic of Utah, Jurassic vegetation and botany, burrowing ornithischians, Oryctodromeus cubicularis, finding fossils and documenting everything, bunny hands in paleoart, and much more!   You can find ReBecca Hunt-Foster's website here: www.rebeccakhunt.com  and learn more about the Dinosaur National Monument here.   Plus dinosaur news about: Taxonomic, palaeobiological and evolutionary implications of a phylogenetic hypothesis for Ornithischia (Archosauria: Dinosauria) A sauropod from the Lower Jurassic La Quinta formation (Dept. Cesar, Colombia) and the initial diversification of eusauropods at low latitudes Featuring the music of Snale https://snalerock.bandcamp.com/releases  Intro: Death of a Dream.  Outro: Sleepyhead. The Text: Fourth Iteration “Inevitably, underlying instabilities begin to appear” (p. 179). This week's text is The Main Road, spanning from pages 181-191. Synopsis: Big Rex knocks down the fences in the storm, and ominously directs her terrifying attention upon everyone in the Land Cruisers. Ed Regis wets his pants and runs away, but everyone else is left in the tyrannosaur's devastating path. Lex's screams are cut off by the lowering of the tyrannosaur's head, Malcolm is flung like a rag doll, Tim is trapped in the Land Cruiser, which the tyrannosaur throws into the top of a tree, and Grant has a moment of discovery, realizing that if he remains absolutely still, the tyrannosaur can't see him – but then it kicks at him, and he blacks out upon hitting the ground.  Discussions surround: Movie adaptations, The Dinosaurs, Believe me, I know! and The Iterations. Corrections: For an upcoming “Allusions” section I was reviewing one of the fundamental biotech companies that Crichton references – and I realized I've been saying and spelling it totally wrong – because I can't see or something? What I've been calling “Genetech” all this time is actually Genentech with a second N stuck in the middle! Side effects:  May cause fits of terror and urination in your pantaloons. Thank you! Find it on iTunes, on Spotify (click here!) or on Podbean (click here). Thank you! The Jura-Sick Park-cast is a part of the Spring Chickens banner of amateur intellectual properties including the Spring Chickens funny pages, Tomb of the Undead graphic novel, the Second Lapse graphic novelettes, The Infantry, and the worst of it all, the King St. Capers. You can find links to all that baggage in the show notes, or by visiting the schickens.blogpost.com or finding us on Facebook, at Facebook.com/SpringChickenCapers or me, I'm on twitter at @RogersRyan22 or email me at ryansrogers-at-gmail.com.  Thank you, dearly, for tuning in to the Juras-Sick Park-Cast, the Jurassic Park podcast where we talk about the novel Jurassic Park, and also not that, too. Until next time!  #JurassicPark #MichaelCrichton  

As a community, living with food allergies is one of the many things that makes us different. At FAACT, we embrace all differences and all people. We're sitting down with change maker and food allergy mom, Ashley Brundage, to help us explore how to empower others while embracing and leveraging our differences to make a change. Ashely is the Founder and President of Empowering Differences, who will discuss her 4-step process of using empowerment to cultivate change. Ashley will also discuss the intersectionality of LGBTQ+ and food allergies.To keep you in the know, below are helpful links:Empowering Differences - Hardcover and eBook plus workbooksEmpowerment Self-AssessmentDifferences Self-AssessmentVoyage of EmpowermentFollow Ashley on Instagram, Facebook, Twitter, Tik TokYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Follow us on Facebook, Twitter, Instagram, LinkedIn, & Pinterest.Sponsored by: Genetech

Sally and Kayla welcome Dr. Serah Kang to discuss her experience applying for academic postdoc positions and industry roles. After completing her PhD, Serah spent two years as a postdoctoral fellow at the Gladstone Institute and now is a senior scientist at Genetech. Serah also discusses how her applications and job decisions were impacted by transhood and how employers can attract and support trans scientists. This is the first in a new series about finding your path after getting your PhD! Stay tuned!! 

Welcome to the Juras-Sick Park-Cast podcast, the Jurassic Park podcast about Michael Crichton's 1990 novel Jurassic Park, and also not about that, too.  Find the episode webpage at: Episode 1 - Introduction "The InGen Incident"  0:00 - Introduction 1:45 - Featuring the Music of SNALE the rock band 2:32 - What dinosaurs did Confractosuchus eat? 3:40 - New Argentinian abelisaur Guemesia ochoai 4:30 - new Iberian titanosaur Abditosaurus kuehnei 5:35 - new Iberian spinosaur Iberospinus natarioi 7:08 - Special guests Phil and Lindsay Longpre 28:45 - Introduction to Jurassic Park. What was the InGen Incident? 30:41 - When did the InGen Incident take place? 34:40 - How does chaos theory connect to Jurassic Park? 35:25 - Crichton's depiction of John Hammond In this episode, my terrific guests Phil and Lindsay Longpre chat with me about Jurassic Park the movie, the novel, ecological criticism, John Hammond, the goldrush, bio technology and more! Plus dinosaur news about: Cretaceous croc confractosuchus sauroktonos (with an unidentified ornithopod) Iberian titanosaur Abditosaurus kuehnei,  Argentinian abelisaur Guemesia ochoai, and  Iberian spinosaur Iberospinus natarioi. Featuring the music of Snale https://snalerock.bandcamp.com/releases  Intro: Hummingbird. Outro: Sacrifice to the Inhuman Creature. The Text: Introduction: “The InGen Incident”                                         ix As a synopsis, this is an essay by Crichton that outlines that biotechnology and genetic engineering have been rushed with furious haste, for profits. The biotechnology revolution differs in three important respects from past scientific transformations. 1)      it is broad-based: 500 corporations spend $5 billion a year on biotechnology 2)      much of the research is thoughtless or frivolous 3)      the work is uncontrolled Most concerning, “no watchdogs are found among scientists themselves.” Scientists are no more ethical in pursuing science than the capitalists pursuing the science (x). The whimsical use of biotechnology should concern us all (ix). And everyone is a stakeholder (x). Science is no longer pursued for the betterment of mankind (x). Galileo proceeded with “science as a free and open inquiry into the workings of nature.” Scientists traditionally operated above politics and war, rebelling against secrecy in research and frowning upon patents – working for the betterment of all mankind. Crichton labels a clear moment when the betterment of all switched to patents for profit: April 1976. Venture capitalist Robert Swanson bankrolled biochemist Hebert Boyer (both real people) to launch Genetech, a real business who's Wikipedia page includes no mention of Jurassic Park… They, standing on the shoulders of giants (those giants being British researchers James Watson and Francis Crick, who deciphered the structure of DNA), launched a trend-setting, gene-splicing new world of genetic engineering enterprise (x). This led to a “significant shift in attitude,” says Crichton (xi). We're told of the “InGen Incident” where fewer than 20 people were on a remote island off the west coast of Costa Rica, in the final two days of August 1989, and only a handful survived. By Oct. 5, 1989, InGen was bankrupt. Discussions surround world building, foreshadowing, Hammond personified,     Take only as recommended: Find it on iTunes, on Spotify (click here!) or on Podbean (click here). Thank you! The Jura-Sick Park-cast is a part of the Spring Chickens banner of amateur intellectual properties including the Spring Chickens funny pages, Tomb of the Undead graphic novel, the Second Lapse graphic novelettes, The Infantry, and the worst of it all, the King St. Capers. You can find links to all that baggage in the show notes, or by visiting the schickens.blogpost.com or finding us on Facebook, at Facebook.com/SpringChickenCapers or me, I'm on twitter at @RogersRyan22 or email me at ryansrogers-at-gmail.com.  Thank you, dearly, for tuning in to the Juras-Sick Park-Cast, the Jurassic Park podcast where we talk about the novel Jurassic Park, and also not that, too. Until next time!  #JurassicPark #MichaelCrichton 

In this episode, we discover a new culinary world of Chinese Cuisine with food allergy advocate, cookbook author, and parent, Sharon Wong. Her new book, Chinese Instant Pot Cookbook, features food allergy substitutions and fast and easy recipes using an Instant Pot. She shows us how food allergies don't stop people from cooking and enjoying delicious Chinese Cuisine.To keep you in the know, here are a few helpful websitesChinese Instant Pot Cookbook: 60 Quick and Easy Classic RecipesNut-Free Wok Blog Soy-Braised Duck Legs with Ginger Scallion Instant Pot RecipeYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by:  Genetech* Please note that today's guest was not sponsored by the Genetech or compensated in any way by the sponsor to participate in this specific podcast.

In recent years, the Food and Drug Administration approved several new treatments specifically for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder. But what about neuroimmunological conditions that do not have FDA approved options and require off-label use of immunomodulatory medications -- conditions like neurosarcoidosis, neuro-Behcet's, or central nervous system involvement of systemic rheumatologic conditions? There is often a lack of rigorous evidence to guide treatment of these conditions, leaving experts to rely on individual or institutional experience. Our guest on this episode is Dr. Jeffrey Gelfand, neuroimmunologist and Associate Professor of Neurology at UCSF. He specializes in treating patients with rare neuroinflammatory conditions, and he'll talk to us about the new drugs for NMO as well as off-label use of immunomodulatory therapies for a range of neurological conditions. Dr. Gelfand was interviewed by ANA producer Dr. Rohini Samudralwar. Series 2, Episode #9 Disclosures: Dr. Gelfand receives research support to UCSF for clinical trial from Rosch and Genetech; provides consulting to Biogen

Approximately 80% of clinical research and genomic studies consist of data from Caucasian participants. Roche and Genetech are determined to change that. Nicole Riche, Global Head of Health Equity and Population Science, reveals how her team developed a pioneering global strategy to address healthcare disparities across the entire product lifecycle to ensure the promise of personalized health care becomes a reality for all patients.

  Planets are lining up California's gonna slide into the sea It's the third great woe It's the thousand-year peace (Spin your partner while you can) No one wants to hear Spoon-feed me the good news forget about the rest Lemmings never fear I repeat, this is only a test I'm much better now I was down there for awhile, I guess I saw the light Oh, it was crazy, anyhow It's no worse than before, I guess you folks were right Yeah, I'm much better now Pass me the chips, turn up the radio I guess I saw the light It's five more miles 'til we get to Idaho   -- Worse; Too Much Joy, 1988     And the hits just keep oooonnnnn comin’! 3rd quarter only got weirder. We tried to return to a degree of normalcy with restaurants, theme parks and even sports re-opening in various forms. One thing that never stopped was the need to secure our data, companies and families. We also needed to figure out how to get people healthy. We talked about how risk and trust relate to controlling the chaos that can be part of security as well as the language and culture of security. We even had time to learn how to connect patients with the healthcare they need.     Chris Blask and Fred Cohen: A Single Tweet Can Destroy Faith in Government Agencies John McClurg: Combating Cyber Chaos with Unified Endpoint Security Chris Morin: How Cybersecurity Physical Security Influence Each Other? Amar Singh: How Do We Rank Trust, Security and Control? Dr Jessica Barker: Language and Culture Have a Profound Impact on Cybersecurity Scott Schober: Bringing Cybersecurity Expertise to the Masses Via Television Robert Willis: Who or What is the Most Choice Hacking Target? Dave Brown and Luke Hull: Defense in Depth: Cliché or Cornerstone of Cybersecurity? Pete Fronte: Helping Patients Understand and Find Relevant Healthcare     About Matt Stephenson           Insecurity Podcast host Matt Stephenson (@packmatt73) leads the Broadcast Media team at BlackBerry, which puts me in front of crowds, cameras, and microphones all over the world. I am the regular host of the InSecurity podcast and video series at events around the globe.   I have spent the last 10 years in the world of Data Protection and Cybersecurity. Since 2016, I have been with Cylance (now BlackBerry) extolling the virtues of Artificial Intelligence and Machine Learning and how, when applied to network security, can wrong-foot the bad guys. Prior to the COVID shutdown, I was on the road over 100 days a year doing live malware demonstrations for audiences from San Diego to DC to London to Abu Dhabi to Singapore to Sydney. One of the funniest things I've ever been a part of was blowing up a live instance of NotPetya 6 hours after the news broke... in Washington DC... directly across the street from FBI HQ... as soon as we activated it a parade of police cars with sirens blaring roared past the building we were in. I'm pretty they weren't there for us, but you never know...   Every week on the InSecurity Podcast, I get to interview interesting people doing interesting things all over the world of cybersecurity and the extended world of hacking. Sometimes, that means hacking elections or the coffee supply chain... other times that means social manipulation or the sovereign wealth fund of a national economy.   InSecurity is about talking with the people who build, manage or wreck the systems that we have put in place to make the world go round...   Can’t get enough of Insecurity? You can find us at Spotify, Apple Podcasts and ThreatVector as well as GooglePlay, Gaana, Himalaya, I Heart Radio and wherever you get your podcasts!   Make sure you Subscribe, Rate and Review!

In Episode 3 of the HemoAware Podcast, Jesse John Francis Clark talks about how Genentech will no longer give the hemophilia community access to the Hemlibra death data. Hemlibra currently has 44 fatalities and that number has grown every time Genetech publishes a new death report. Find out what Jesse John Francis Clark thinks on episode 3 of the HemoAware Podcast.

FAACT's Medical Advisory Board Chair, Shahzad Mustafa, MD, sits down with us six months after our first podcast addressing the beginning of the COVID-19 Pandemic. Dr. Mustafa, in his usual warm and caring style, discusses the upcoming flu season, decision fatigue, managing an allergic reaction at home, and why self-care is critical. He also shares insight into what FAACT's Diversity, Equity, and Inclusion Advisory Board means to him personally.To keep you in the know, below are a few, free and helpful links to our downloadable materials:FAACT's COVID-19 Resource CenterAmerican College of Allergy, Asthma, and ImmunologyAmerican Academy of Allergy, Asthma, and ImmunologyJohns Hopkins Coronavirus Resource CenterYou can find the FAACT Roundtable Podcast on Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: Genetech

We're speaking with inspirational author, advocate, and TV and radio personality, Elizabeth Hamilton-Guarino, about how she uses her voice to impact others. Elizabeth, a FAACT Spokesperson, has penned a new children's food allergy book to support students with food allergies. She recently released a journal to inspire calm and self-discovery during these turbulent times.To keep you in the know, below are a few, free and helpful links to our downloadable materials:A Lesson for Every Child - By Sally Huss with Elizabeth Hamilton-GuarinoBest Ever You Journal - By Elizabeth Hamilton-Guarino and Kris FullerPercolate - Let Your Best Self Filter Through - By Elizabeth Hamilton-GuarinoCompassion in a Time of Chaos: There is No Right Response - FAACT BlogFAACT's Self-care SectionFAACT's Facebook LIVE Video: Self-care Is for Everyone!You can find the FAACT Roundtable Podcast on Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by: Genetech

Marc Lesser is a Zen teacher who leads trainings and talks worldwide. He has led mindfulness and emotional intelligence programs at many of the world's leading businesses and organizations including Google, Genetech and Kaiser. He's currently CEO of ZBA Associates, a company providing mindfulness-based leadership trainings and creating community by supporting ongoing groups. Previously, he served as CEO and co-founder of Search Inside Yourself Leadership Institute, whose core programs he helped develop within Google. Marc was a resident of the San Francisco Zen Center for 10 years and former director of Tassajara, Zen Mountain Center. His books include Less: Accomplishing More by Doing Less (New World Library 2009), Know Yourself, Forget Yourself (New World Library 2013) and Seven Practices of a Mindful Leader: Lessons From Google and a Zen Monastery Kitchen (New World Library 2019).Interview Date: 6/7/2019       Tags: MP3, Marc Lesser, mindfulness, Norman Fischer, vulnerability, deep listening, ground truth, conflict, failure, Zen, business world, negativity bias, cultivating trust, building trust, connection, Meditation, Philosophy, Personal Transformation, Buddhism, Work/Livelihood

Mark Bley has worked in the Construction Industry for over 30 years. He has been on Dome Construction's staff since 1981 and has been President & CEO since 2008. Before becoming President & CEO, Mark acted as Project Manager on Dome Construction's staff for 24 years. His work experience prior to joining Dome includes heavy construction and electrical utility construction and design. To keep young, Mark has mentored 7 boys through Urban Services YMCA Building Futures programs. He is strongly committed to giving our youth every opportunity for their future. Both he and Dome Construction are sponsoring Urban Services Empowerment to Employment (E2E), Genesys Works, and Immaculate Conception Academy and All Stars workforce development programs to assist our youth to become productive. He is on the Board for the All Stars Project. My interview with Mark covers his “prodigal son” beginnings in the construction industry. How he returned and thrived at his father’s company by building unique projects for companies like Genetech that he found interesting and challenging. We also explore how Mark avoids the traditional top down command and control leadership model that many construction companies use, in favor of pushing power out to a variety of construction groups that are responsible for developing and executing their own business plans that integrate together into the overall business plan of the company.   Finally we hit on Mark’s advice for growing a construction company, his perspective on mistakes, and what Mark is doing to prepare his business to be passed onto the next generation.   Show Notes: Mark’s “Prodigal Son” beginnings. How building the first large scale Genetech project hooked Mark back into construction Mark’s personal pursuit of projects that interested him. Taking responsibility for Dome’s pharmaceutical construction group. How Mark leveraged his personal insight of pursuing interesting projects into growing the company as President and CEO. Structuring Dome into groups (based specific industries) and allowing the groups to determine their destinies. Combining the goals of the individual groups with the overall company goals. The positive aspects of avoiding “command and control” leadership. Moving from industry specific groups to client specific groups. The goal of perpetuating the business to the next generation by delegating responsibility, teaching business planning, and allowing people to pursue projects that interest them. How moving away from a “command and control” structure makes the company more dynamic and efficient. Mark’s outlook on mistakes: It’s not a failure, it’s something we tried and didn’t work We are committed to learn from it We make sure the whole company benefits from the learning opportunity How to grow your construction company: Encourage people to pursue projects and clients that interest them Use a common set of metrics that everyone understands and that everyone is accountable for Praise people’s accomplishments Mark’s San Francisco restaurant recommendation: Coi   Additional Links: Dome Construction Mark Bley’s LinkedIn Profile   This episode is brought to you by The Construction Leaders Dashboard. The Construction Leaders Dashboard is one of the simplest and yet most powerful tools for leaders in construction companies of all sizes.    Construction companies use this tool to get clear on strategic priorities, recruit new field and office talent who are aligned with the mission and values of the firm, and as a development planning tool to develop the next generation of leaders. It will empower you to: Focus on what matters, so that you spend your time doing the things that have the most impact with clients. Make sure that everyone in the organization is aligned, accountable, and contributing equally to the company’s growth and success.   Attract, develop, and retain future leaders who can continue to move the organization forward. To instantly download your copy of the dashboard, go to: https://www.ericanderton.com/cld

In this edition of Occupation Station, Dr. Whitney Kirschbrown, a Scientist in Clinical Pharmacology at Genentech in South San Francisco, California, talks about her role in pharmacokinetic, drug interaction, and exposure-response analyses that help guide prescribing information in the drug label. Dr. Kirschbrown shares some advice for today’s students. She advises student to engage with faculty and staff at ACPHS and be open to the many opportunities they can help guide you toward.

Dr. Helen Figge, Chief Communications and Public Relations Officer at CareFully Inc. and a member of the President’s Advisory Council, has an inspirational story with many interesting career changes along the way. In this two part episode, Dr. Figge talks about why she thinks the curriculum at ACPHS will give students the versatility to branch out in so many directions. Dr. Figge also has some great advice for students about listening, taking chances, and even growing through making mistakes. Part One of Two

Siri and Joven host this episode of Express Yourself! with a theme of Truth. They interview Marc Lesser, who blended his leadership experience running a Zen monastery kitchen, leading mindfulness trainings for Google engineers, and starting and running the Search Inside Yourself Leadership Institute to write the new book, Seven Practices of a Mindful Leader, Lessons from Google and a Zen Monastery Kitchen. Marc shares experiences from his life while listening to what the teens have to say about theirs. The Gift of Truth by Henry Ammar from the book, Be the Star You Are! Millennials to Boomers Celebrating Gifts of Positive Voices in a Changing Digital World is read by the hosts and in the final segment, they share their definition of truth. An exhilarating hour of sharing and mindful training with an insightful, humble human.

Siri and Joven host this episode of Express Yourself! with a theme of Truth. They interview Marc Lesser, who blended his leadership experience running a Zen monastery kitchen, leading mindfulness trainings for Google engineers, and starting and running the Search Inside Yourself Leadership Institute to write the new book, Seven Practices of a Mindful Leader, Lessons from Google and a Zen Monastery Kitchen. Marc shares experiences from his life while listening to what the teens have to say about theirs. The Gift of Truth by Henry Ammar from the book, Be the Star You Are! Millennials to Boomers Celebrating Gifts of Positive Voices in a Changing Digital World is read by the hosts and in the final segment, they share their definition of truth. An exhilarating hour of sharing and mindful training with an insightful, humble human.

采访 制作丨徐涛 校对丨秘丛丛 （以下文字只是音频节目的少许补充。「硅谷早知道」每周周五中午12点准时更新，敬请期待。） 对于一个对医药行业并不是很了解的记者而言，药明生物是个让人有点费解，但也有趣的公司。 费解在于，生物制药是个太过于专业的领域，如果不做一些功课，你很难理解它在做什么，比如，为何在2015年从母公司药明康德独立出来，又是如何做到在2017年于港交所上市的。 而有趣之处在于，为了让外行更加理解这家公司的商业模式，这家公司身上不断被安上一些类比：例如有人说它是医药行业的富士康；药明生物认为自己是医药行业的淘宝或者台积电；在访谈后半截，我觉得把它比作医药行业的AWS更合适。 我想这也是我在这次访谈获得的最大的收获之一。我看到这家生物制药行业的公司也在不断学习别的行业的公司，例如阿里和华为。除此之外，这家公司对于如何创新，如何利用中国的人才优势，如何思考自己的商业模式，有着自己的看法和经验，看起来也的确可以被别的行业借鉴。 更多详细解读，请在36氪App搜索《硅谷早知道》，订阅并收听这期音频节目，Enjoy！ 本期嘉宾 陈智胜，药明生物CEO。在此之前，曾任上海康岱生物CEO、上海赛金生物COO、礼来高级工程顾问。也曾在默克担任要职，是美国特拉华大学化学工程博士。 提及名词 药明康德，是制药、生物技术以及医疗器械研发开放式能力和技术平台公司，为全球客户提供创新医药研发服务。公司成立于2000年，总部位于中国上海。 药明生物，是药明康德集团旗下的生物制药研发、生产服务企业，成立于2011年。 台积电，台湾积体电路制造股份有限公司，属于半导体制造公司。成立于1987年，是全球第一家专业积体电路制造服务企业，总部与主要工厂位于台湾新竹科学园区。 基因泰克（Genetech），美国基因工程技术公司，是由风险投资家Robert A. Swanson和生物化学家Herbert Boyer博士于1976创立的生物技术公司，被认为是生物技术行业的创始者。瑞士罗氏制药集团在2009年3月26日出资约468亿美元全额收购了该公司。 NIH, National Institutes of Health ，美国国立卫生研究院，是美国最高水平的医学与行为学研究机构，初创于1887年，任务是探索生命本质和行为学方面的基础知识。 相关阅读 投资人去CES的少了？他们可能在旧金山的这场大会 (https://36kr.com/p/5171687) 深度剖析新药研发模式，合作开发、项目购买逐渐兴起 (https://36kr.com/p/5164363) 我就是药神 (https://36kr.com/p/5156762)

In this episode, BSI has the honor of interviewing Wai Poc. Wai is Executive Coach at Unleashed Leaders in Silicon Valley. His clients have included Google, Nintendo, Zynga, Mozilla, Intel, Facebook, Genetech and many others. Wai shares during this interview the critical keys to attracting and retaining the best talent and how important workplace culture is. This interview is filled with keen insight from a veteran organizational consultant. For more information about Wai Poc and Unleashed Leaders please check out www.UnleashedLeaders.com --- Support this podcast: https://anchor.fm/businessscaleinsights/support

You'll know our guest from iconic sitcoms such as Mama's Family and The Carol Burnett Show as well as her new starring role on the FOX comedy, The Cool Kids. Vicki Lawrence has made millions of Americans laugh but, she's not laughing about a condition that she and an estimated 1.5 million Americans suffer from - CIS (Chronic Idiopathic Urticaria). Vicki quickly realized there were limited resources for people living with CIS - a skin condition characterized by hives and welts that can last for months or even years. Determined to take charge, she joined an educational program supported by the Asthma and Allergy Foundation of America and made possible by Genetech and Novartis.  www.ciuandyou.com/#vicki-personal-story https://www.gene.com/ https://www.novartis.com/    

For the full show notes visit https://jeffagostinelli.com/podcast/bonniekelly/  What does it mean to seek better than the norm, to truly live an extraordinary life? Our life experiences and the meaning we attach to them create who we are and shape our reality. Bonnie opens this beautifully by saying "what you believe is what you perceive." On our journey to becoming whole, addressing our deeply held beliefs about who we are is the springboard for true healing and creating the life you envision. Bonnie Kelly teaches people how to de-weed their minds of underlying Negative Core Beliefs and cultivate a beautiful garden of emotional health and balance. As an author, personal development and emotional intelligence expert, motivational speaker and founder of Bonnie Kelly & Associates and MindFu Academy™, Bonnie has dedicated her life to helping others stop the cycle of self-sabotage. From her experiences as an abused child to her life on the streets as a teen to being in and out of jail and rehab, she has experienced life's lowest points firsthand. When she hit rock bottom, she became determined to change her life for the better. Now, she is supporting individuals, groups and businesses in understanding what it means to operate from a place of emotional clarity and wellness. Corporate groups she has worked with include Genetech, Union Pacific, California Nurses Association, Solano County Probation Department, Benicia USD, Keller Williams and Brandman University. At the heart of Bonnie's work is her year long Emotional Resilience Training program, which helps people end patterns of unconscious self-sabotage and transform their lives for the better. Her new book is entitled, “True to Your Core: Uncovering the Subconscious Beliefs Wreaking Havoc in Your Life.” Today we dive into Bonnie's book, True to Your Core and unpack what it means to create an extraordinary life. In this episode you'll learn How to let go of the old programming that leads to mental and emotional suffering Ways to “win the war of your worth” by turning down the critical inner voice Understanding how your emotional state impacts your decisions, actions, and the people around you Ways to unpack and rewire the subconscious beliefs that make you feel unworthy How to move forward and find a new path after losing your identity Why the muscles of self-development need to be trained on a regular basis Strategies to overcome procrastination and avoid self-sabotage How to make sure you don't settle for a less than extraordinary life and MORE…

Ready to get out of your own way and on with your life? I had the best interview with Bonnie Kelly on this episode of the SWP! We chatted the power of association, living your highest truth, changing your negative beliefs to positive beliefs and following your bliss!   Bonnie Kelly teaches people how to de-weed their minds of underlying Negative Core Beliefs and cultivate a beautiful garden of emotional health and balance. As an author, personal development and emotional intelligence expert, motivational speaker and founder of Bonnie Kelly & Associates and MindFu Academy™, Bonnie has dedicated her life to helping others stop the cycle of self-sabotage. From her experiences as an abused child to her life on the streets as a teen to being in and out of jail and rehab, she has experienced life's lowest points firsthand. When she hit rock bottom, she became determined to change her life for the better. Now, she is supporting individuals, groups and businesses in understanding what it means to operate from a place of emotional clarity and wellness. Corporate groups she has worked with include Genetech, Union Pacific, California Nurses Association, Solano County Probation Department, Benicia USD, Keller Williams and Brandman University. At the heart of Bonnie's work is her year long Emotional Resilience Training program, which helps people end patterns of unconscious self-sabotage and transform their lives for the better. Her new book is entitled, “True to Your Core: Uncovering the Subconscious Beliefs Wreaking Havoc in Your Life.” For more information, visit www.BonnieKelly.meand www.MindFuAcademy.com. Let's get deeper and play bigger in the I AM WORTHY Community! Come join me and our thousands-strong tribe of Spirit Rebels.   Visit Bonnie's website: http://bonniekelly.me/ Connect with Bonnie on Facebook: https://www.facebook.com/bonnie.kelly123 Take the FREE 5-Day I AM WORTHY Challenge and let's raise your money vibes and charge your worth. Join the Tribe! www.ryanyokome.com/worthy See you in the community spirit homie! Much Love, Ryan Yokome Breakthrough Coaching PS: We would love to hear from you! For questions, coaching, or to book interviews, please email my assistant Brandi at brandi@ryanyokome.com  

1) Early Decompressive Craniectomy for Malignant Cerebral Infarction: Meta-analysis and Clinical Decision Algorithm2) What's Trending: Update on the Resident and Fellows section 3) Topic of the Month: Brain tumors - gliomasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 28, 2017 issue of Neurology. In the first segment, Dr. Bryan Eckerle talks with Dr. Bradley Molyneaux and Dr. Christopher Streib about their Neurology® Clinical Practice paper on early decompressive craniectomy for malignant cerebral infarction. Dr. Ted Burns talks with Dr. Roy Strowd about recent updates regarding the Neurology® Resident & Fellows section for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. David Schiff on gliomas. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Molyneaux has received research support from Remedy Pharmaceuticals, Inc.Dr. Streib has served on the Institute for Clinical Systems Improvement (ICSI) Stroke Guidelines Committee (no reimbursement).Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.Dr. Schiff has served on the scientific advisory boards of Genetech, Celldex, Orbus, and Vascular Biogenics Oxigene; has received travel funding/speaker honoraria from Merck; serves on the editorial boards of Neurology, Neurosurgery, Neuro-Oncology, and Lancet Neurology; receives publishing royalties from UpToDate, and has been a consultant for Cavion.All other participants report no disclosures.

1) Guideline on prevention of stroke in nonvalvular atrial fibrillation. and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Gary Gronseth about AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington is reading our e-Pearl of the week about superficial siderosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices and any other options. The participants had nothing to disclose except Drs. Kissela, Gronseth, Addington, Southerland and Chaturvedi.Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews.Dr. Gronseth serves as Associate Editor for for Neurology®; serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Clinical specificities of patients with NMDA receptor antibodies encephalitis and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Jerome Honnorat about his paper on the clinical specificities of patients with NMDA receptor antibodies encephalitis. Dr. James Addington is reading our e-Pearl of the week about posterior interosseous nerve syndrome. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Apixaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Addington and Chaturvedi.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) ASA/clopidogrel combination confers better long term vascular protection in ASA failure and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Robert Cote about his paper on whether the combination of ASA/clopidogrel confers better long term vascular protection in ASA failure. Dr. James Addington is reading our e-Pearl of the week about hypoglycorrhachia. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Dabigatran), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Cote, Addington, Southerland and Chaturvedi.Dr. Cote served on the scientific advisory board for Bayer Schering Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer Inc; serves on the scientific advisory board for DSMB for National Institute of Health (Point Study), Steering committee for the National Institute of Health (SPS3 study); is a consultant for Otsuka Pharmaceutical Co., Ltd.; received speaker honoraria from Boehringer Ingelheim, Merck Serono, Sanofi-aventis.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Primary leptomeningeal lymphoma and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Schiff about his paper on primary leptomeningeal lymphoma. Dr. Roy Strowd is reading our e-Pearl of the week about anti-NMDA receptor encephalitis. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about definitions and etiology of functional symptoms and conversion disorder. The participants had nothing to disclose except Drs. Burns, Schiff, Strowd and Stone.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Schiff serves as an editorial board member of Neurology® and Neurosurgery; received travel related expenses without personal compensation from Merck Sereno; serves on the scientific advisory board for Genetech, Inc.; is a consultant without personal compensation for Tau Therapeutics; serves on the data and safety monitoring boards for Celldex Therapeutics, Inc. and Vascular Biogenics Ltd. and receives royalties from UptoDate.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.

This podcast is on the use of Erivedge with Brent Moody MD and was recorded at the 2013 Summer SDPA Conference in St. Louis.

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor.Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri.Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.

1) Measures of health-related quality of life and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Cella about his paper on measures of health-related quality of life. Dr. Stacey Clardy is reading our e-Pearl of the week about frontotemporal dementia. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about major categories of memory. Next week they will discuss bedside testing of memory. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cella serves on the scientific advisory boards of the Moffitt Cancer Center, NCI Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee, serves as Associate Editor of The Journal of Supportive Oncology; is a consultant for Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, and GlaxoSmithKline; receives royalties from Up-to-Date annual review of Quality of life measures; receives research support from Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, GlaxoSmithKline and AVEO Pharmaceuticals, Inc.; and is funded by the NIH.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.